Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/31646| Title: | A mixed blessing for liver transplantation patients - Rapamycin. | Austin Authors: | Fan, Guang-Han;Zhang, Chen-Zhi;Gao, Feng-Qiang;Wei, Xu-Yong;Ling, Sun-Bin;Wang, Kai;Wang, Jian-Guo;Zheng, Shu-Sen;Nikfarjam, Mehrdad ;Xu, Xiao | Affiliation: | Department of Hepatobiliary and Pancreatic Surgery, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou 310006, China. State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer, Guangzhou 510060, China. Department of Hepatobiliary and Pancreatic Surgery, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou 310006, China; Key Laboratory of Integrated Oncology and Intelligent Medicine of Zhejiang Province, Hangzhou 310006, China; Institute of Organ Transplantation, Zhejiang University, Hangzhou 310003, China. Institute of Organ Transplantation, Zhejiang University, Hangzhou 310003, China; Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China; Department of Hepatobiliary and Pancreatic Surgery, Shulan (Hangzhou) Hospital, Hangzhou 310000, China; NHC Key Laboratory of Combined Multi-Organ Transplantation, Hangzhou 310003, China. Surgery (University of Melbourne) Zhejiang University School of Medicine, Hangzhou 310058, China; Key Laboratory of Integrated Oncology and Intelligent Medicine of Zhejiang Province, Hangzhou 310006, China; Institute of Organ Transplantation, Zhejiang University, Hangzhou 310003, China; Westlake Laboratory of Life Sciences and Biomedicine, Hangzhou 310024, China. Institute of Organ Transplantation, Zhejiang University, Hangzhou 310003, China. |
Issue Date: | Feb-2023 | Date: | 2022 | Publication information: | Hepatobiliary & Pancreatic Diseases International: HBPD INT 2023; 22(1) | Abstract: | Liver transplantation (LT) is an effective treatment option for end-stage liver disease. Mammalian target of rapamycin (mTOR) inhibitors, such as rapamycin, are widely used post LT. | URI: | https://ahro.austin.org.au/austinjspui/handle/1/31646 | DOI: | 10.1016/j.hbpd.2022.10.004 | ORCID: | Journal: | Hepatobiliary & Pancreatic Diseases International: HBPD INT | PubMed URL: | 36328894 | Type: | Journal Article | Subjects: | Hepatocellular carcinoma Liver transplantation Metabolic disease Rapamycin Tumor recurrence |
| Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.